Operating Cash Flow CAGR:16.84%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Operating Cash Flow CAGR averages 21.01% over 3 years and 14.23% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash STERIS plc generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
STE Operating Cash Flow CAGR Chart
STERIS plc (STE)
STE Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
STE Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | $1.15B | $1.34B | +$193.31M | +16.84% | +16.84% |
| 2025 | $973.27M | $1.15B | +$174.81M | +17.96% | +17.96% |
| 2024 | $756.95M | $973.27M | +$216.33M | +28.58% | +28.58% |
| 2023 | $684.81M | $756.95M | +$72.14M | +10.53% | +10.53% |
| 2022 | $689.64M | $684.81M | $-4.83M | -0.70% | -0.70% |
| 2021 | $590.56M | $689.64M | +$99.08M | +16.78% | +16.78% |
| 2020 | $539.50M | $590.56M | +$51.05M | +9.46% | +9.46% |
| 2019 | $457.63M | $539.50M | +$81.87M | +17.89% | +17.89% |
| 2018 | $424.09M | $457.63M | +$33.55M | +7.91% | +7.91% |
| 2017 | $254.68M | $424.09M | +$169.41M | +66.52% | +66.52% |
| 2016 | $246.04M | $254.68M | +$8.63M | +3.51% | +3.51% |
| 2015 | $209.63M | $246.04M | +$36.41M | +17.37% | +17.37% |
| 2014 | $227.81M | $209.63M | $-18.18M | -7.98% | -7.98% |
| 2013 | $149.37M | $227.81M | +$78.44M | +52.52% | +52.52% |
| 2012 | $117.74M | $149.37M | +$31.63M | +26.86% | +26.86% |
| 2011 | $224.95M | $117.74M | $-107.21M | -47.66% | -47.66% |
| 2010 | $167.38M | $224.95M | +$57.57M | +34.39% | +34.39% |
| 2009 | $143.40M | $167.38M | +$23.98M | +16.72% | +16.72% |
| 2008 | $95.74M | $143.40M | +$47.66M | +49.78% | +49.78% |
| 2007 | $161.96M | $95.74M | $-66.22M | -40.88% | -40.88% |
| 2006 | $148.87M | $161.96M | +$13.09M | +8.79% | +8.79% |
| 2005 | $129.13M | $148.87M | +$19.73M | +15.28% | +15.28% |
| 2004 | $133.29M | $129.13M | $-4.16M | -3.12% | -3.12% |
| 2003 | $142.02M | $133.29M | $-8.73M | -6.15% | -6.15% |
| 2002 | $102.34M | $142.02M | +$39.68M | +38.78% | +38.78% |
| 2001 | $71.11M | $102.34M | +$31.23M | +43.92% | +43.92% |
| 2000 | $64.50M | $71.11M | +$6.61M | +10.24% | +10.24% |
| 1999 | $12.00M | $64.50M | +$52.50M | +437.50% | +437.50% |
| 1998 | $16.30M | $12.00M | $-4.30M | -26.38% | -26.38% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q4 2026 | $335.40M | +12.5% | +28.6% |
| Q3 2025 | $298.20M | +3.6% | -10.4% |
| Q2 2025 | $287.80M | -31.5% | +14.8% |
| Q1 2025 | $420.00M | +61.1% | +38.3% |
| Q4 2025 | $260.78M | -21.6% | +2.3% |
| Q3 2024 | $332.84M | +32.7% | +14.3% |
| Q2 2024 | $250.77M | -17.4% | +71.6% |
| Q1 2024 | $303.70M | +19.2% | +8.0% |
| Q4 2024 | $254.81M | -12.5% | +18.1% |
| Q3 2023 | $291.24M | +99.4% | +41.7% |
| Q2 2023 | $146.09M | -48.0% | +40.7% |
| Q1 2023 | $281.13M | +30.3% | +21.3% |
| Q4 2023 | $215.80M | +5.0% | +25.7% |
| Q3 2022 | $205.58M | +98.0% | -15.9% |
| Q2 2022 | $103.82M | -55.2% | -39.4% |
| Q1 2022 | $231.75M | +34.9% | +137.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About STERIS plc
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- CEO
- Daniel A. Carestio